Back to Rankings

PROF

Profound MedicalC
Nasdaq / Health Care Equipment & Services
Last Price
At close
2026-07-22
View Chart
Current thesis
The bullish case is that 2025 showed real top-line traction: revenue rose 51% to $16.1M, recurring non-capital revenue rose to $9.73M, and management is explicitly investing behind direct sales and utilization growth for TULSA-PRO [#10-K-2026-03-05]. If quarterly updates confirm continued system placements and procedure growth, the current micro-cap valuation can rerate quickly.
Posture
Mixed
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite.
What can break
Commercial adoption of TULSA-PRO may remain slower than the cost ramp behind the direct sales build-out.
Momentum
70
Value
37
Sentiment
55
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $7.25 · Bull $9.50 · Bear $4.25
Data freshness
Prices
As of 2026-07-22
Fundamentals
As of 2026-07-22 • Vendor: Data Vendor v1
Scores
As of 2026-07-22 • Model: HYBRID_IC_RP
AI Memo
As of 2026-04-18 • Model: RankAlpha Sentiment Codex
Investment thesis
As of 2026-07-22
Supporting evidence
What
Grade C · Mixed
Confidence Medium · Net Neutral
Target $11.14
Why
Momentum70 · Δ7d -
Value37 · Δ7d +0.0
Sentiment55 · Δ7d -
So what
Balanced signals (Net Neutral). Wait for confirmation before sizing up.
Lead driver: Momentum · See technicals
Momentum
70
26% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Value
37
39% active weight
Current posture
7d trendFlat
Δ7d
+0.0
Δ21d
+0.1
Sentiment
55
34% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Why this grade

Composite grade C. Momentum 70.5 / Value 36.5 / Sentiment 54.6

Fundamentals (TTM)
As of 2026-07-22
Market Cap
$255.88M
Beta
0.29
Shares Out
36.34M
P/E (TTM) · Derived
-5.0
P/S (TTM)
19.14
P/FCF (TTM) · Derived
-5.70
Rev YoY
+103.6%
EPS YoY
-45.6%
Gross Margin
+71.1%
Op Margin
-295.4%
Net Debt
-$55.01M
Current Ratio
6.56
As of 2026-07-22 • Updated nightlySource: Internal modelMethodology